- Home
- Publications
- Publication Search
- Publication Details
Title
Bispecific Antibodies: From Research to Clinical Application
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-05
DOI
10.3389/fimmu.2021.626616
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- (2020) Marion Subklewe et al. BLOOD
- Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
- (2020) Aurelia H. M. de Vries Schultink et al. CLINICAL PHARMACOKINETICS
- DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
- (2020) Patrick J. Engelberts et al. EBioMedicine
- The BiTE (Bispecific T‐Cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
- (2020) Hermann Einsele et al. CANCER
- A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
- (2020) Yuexian Zhou et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
- (2020) Nancy L. Bartlett et al. BLOOD
- Emicizumab for the treatment of acquired hemophilia A
- (2020) Paul Knoebl et al. BLOOD
- Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology
- (2020) Alison Betts et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Characterization of a Novel FLT3 BiTE® Antibody Construct for the Treatment of Acute Myeloid Leukemia
- (2020) Bettina Brauchle et al. MOLECULAR CANCER THERAPEUTICS
- Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study
- (2020) Y. Touchefeu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
- (2020) Shuyu Huang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies
- (2020) Gaili Guo et al. PROTEIN EXPRESSION AND PURIFICATION
- Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
- (2020) Christophe Schmitt et al. THROMBOSIS AND HAEMOSTASIS
- Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia
- (2020) Manon Queudeville et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia
- (2020) Juan Felipe Combariza et al. Clinical Lymphoma Myeloma & Leukemia
- Emerging Structure–Function Paradigm of Endocrine FGFs in Metabolic Diseases
- (2019) Yongde Luo et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Single-Chain Variable Fragment-based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
- (2019) Raoufeh Ahamadi-Fesharaki et al. Molecular Therapy-Oncolytics
- Advances in antibody engineering for rheumatic diseases
- (2019) Anja S. Schmid et al. Nature Reviews Rheumatology
- Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
- (2019) Christina L. Zuch de Zafra et al. CLINICAL CANCER RESEARCH
- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.
- (2019) Mark Rosenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models
- (2019) Hoan N. Le et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies
- (2019) Sylvia Dietrich et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
- (2019) Claudio Sustmann et al. mAbs
- AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment
- (2019) Shih-Feng Cho et al. Clinical Lymphoma Myeloma & Leukemia
- ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
- (2019) Mark A Rosenthal et al. NEURO-ONCOLOGY
- MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model
- (2018) Hoan N. Le et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
- (2018) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
- (2018) Olivia Campagne et al. CLINICAL CANCER RESEARCH
- Emicizumab-kxwh: First Global Approval
- (2018) Lesley J. Scott et al. DRUGS
- Development of MGD007, a gpA33 x CD3 bispecific DART® protein for T-cell immunotherapy of metastatic colorectal cancer
- (2018) Paul A Moore et al. MOLECULAR CANCER THERAPEUTICS
- FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
- (2018) E. Dianne Pulte et al. ONCOLOGIST
- Bispecific antibodies: design, therapy, perspectives
- (2018) Sergey Sedykh et al. Drug Design Development and Therapy
- Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT
- (2018) Foubert Fanny et al. Oncotarget
- ABT-122, a Bispecific DVD-Immunoglobulin Targeting TNF- and IL-17A, in RA With Inadequate Response to Methotrexate: A Randomized, Double-Blind Study
- (2018) Mark C. Genovese et al. Arthritis & Rheumatology
- Rheumatoid arthritis
- (2018) Nature Reviews Disease Primers
- Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults
- (2018) S.O. Ali et al. CLINICAL MICROBIOLOGY AND INFECTION
- Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting
- (2018) Shiyong Gong et al. METHODS
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- (2018) Johnny Mahlangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Variable heavy–variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly
- (2018) Joerg Thomas Regula et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies
- (2018) Laurent Peyrin-Biroulet et al. AUTOIMMUNITY REVIEWS
- Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A
- (2018) Paul Knöbl DRUGS
- A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer
- (2018) Weihua Hou et al. INVESTIGATIONAL NEW DRUGS
- Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
- (2018) Eric Hatterer et al. mAbs
- Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974
- (2018) Hirotake Shiraiwa et al. METHODS
- ZW25 Effective in HER2-Positive Cancers
- (2018) Cancer Discovery
- Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
- (2018) Daniel G. Guy et al. Current Hematologic Malignancy Reports
- Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab
- (2017) Anne C. Wilke et al. Expert Opinion On Drug Safety
- A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G 1
- (2017) Camilla De Nardis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets
- (2017) Shiyong Gong et al. mAbs
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening
- (2017) Hok Seon Kim et al. PROTEIN ENGINEERING DESIGN & SELECTION
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- Next Generation Antibody Therapeutics Using Bispecific Antibody Technology
- (2017) Tomoyuki Igawa YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
- (2017) Sandra L. Ross et al. PLoS One
- An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
- (2016) Steven R. Leong et al. BLOOD
- Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
- (2016) Antonio Jimeno et al. CANCER
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Abstract 873: A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance
- (2016) Ling Liu et al. CANCER RESEARCH
- Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
- (2016) U. Reusch et al. CLINICAL CANCER RESEARCH
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
- (2016) S. Lehmann et al. CLINICAL CANCER RESEARCH
- Nanobodies as therapeutics: big opportunities for small antibodies
- (2016) Sophie Steeland et al. DRUG DISCOVERY TODAY
- Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- (2016) Jörg T Regula et al. EMBO Molecular Medicine
- Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain
- (2016) Kapil Gadkar et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
- (2016) Katharine D. Grugan et al. mAbs
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
- (2016) P. Bru nker et al. MOLECULAR CANCER THERAPEUTICS
- Blinatumomab: A novel, bispecific, T-cell engaging antibody
- (2015) M. B. May et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- FRI0164 Safety, Tolerability, And Functional Activity of ABT-122, A Dual TNF- and IL-17A–Targeted DVD-IG™, Following Single-Dose Administration in Healthy Subjects
- (2015) H. Mansikka et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- The use of combinations of monoclonal antibodies in clinical oncology
- (2015) Linda M. Henricks et al. CANCER TREATMENT REVIEWS
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Acquired haemophilia: an overview for clinical practice
- (2015) Craig M. Kessler et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- Fab-based bispecific antibody formats with robust biophysical properties and biological activity
- (2015) Xiufeng Wu et al. mAbs
- A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
- (2015) Gurunadh R. Chichili et al. Science Translational Medicine
- The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
- (2015) Maarten Van Roy et al. ARTHRITIS RESEARCH & THERAPY
- Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
- (2015) Nicolas Fischer et al. Nature Communications
- A pretargeting system for tumor PET imaging and radioimmunotherapy
- (2015) Françoise Kraeber-Bodéré et al. Frontiers in Pharmacology
- Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
- (2015) Ganesh Kolumam et al. EBioMedicine
- FRI0303 Discovery and Characterization of Abt-122, an Anti-TNF/IL-17 Dvd-Ig™ Molecule as A Potential Therapeutic Candidate for Rheumatoid Arthritis
- (2014) C.-M. Hsieh et al. ANNALS OF THE RHEUMATIC DISEASES
- Bispecific T-cell engagers for cancer immunotherapy
- (2014) Amelia M Huehls et al. IMMUNOLOGY AND CELL BIOLOGY
- Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer
- (2014) Jonathan S. Berek et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
- (2014) Uwe Reusch et al. mAbs
- A Two-in-One antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions
- (2014) Chingwei V Lee et al. mAbs
- Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
- (2014) Yiren Xu et al. mAbs
- ANG4043, a Novel Brain-Penetrant Peptide-mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
- (2014) A. Regina et al. MOLECULAR CANCER THERAPEUTICS
- Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer
- (2014) Jae Myoung Suh et al. NATURE
- Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
- (2014) Steven M Lewis et al. NATURE BIOTECHNOLOGY
- Controlled Fab-arm exchange for the generation of stable bispecific IgG1
- (2014) Aran F Labrijn et al. Nature Protocols
- Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets
- (2014) D. E. Furst et al. RHEUMATOLOGY
- Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
- (2014) Y. J. Yu et al. Science Translational Medicine
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Two-in-One antibodies with dual action Fabs
- (2013) Charles Eigenbrot et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
- (2013) A. F. Labrijn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
- (2013) J. A. Couch et al. Science Translational Medicine
- A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
- (2013) Hannah Byrne et al. TRENDS IN BIOTECHNOLOGY
- Pseudomonas aeruginosa: new insights into pathogenesis and host defenses
- (2013) Shaan L. Gellatly et al. Pathogens and Disease
- Bispecific Antibody-Mediated Detection of the Staphylococcus aureus Thermonuclease
- (2012) Sarah J. Wagstaffe et al. ANALYTICAL CHEMISTRY
- Catumaxomab
- (2012) James E. Frampton DRUGS
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
- (2012) M Aigner et al. LEUKEMIA
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- A Bispecific Antibody Based Assay Shows Potential for Detecting Tuberculosis in Resource Constrained Laboratory Settings
- (2012) Susmita Sarkar et al. PLoS One
- Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)
- (2012) Diane Seimetz Journal of Cancer
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies
- (2011) M. Muda et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
- (2010) Claudia Bluemel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse
- (2010) Klementina Fon Tacer et al. MOLECULAR ENDOCRINOLOGY
- SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†
- (2010) Jonathan H. Davis et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents
- (2009) Pier Paolo Mainenti et al. ABDOMINAL IMAGING
- Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)
- (2009) Martin Sebastian et al. JOURNAL OF IMMUNOTHERAPY
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
- (2009) J. Bostrom et al. SCIENCE
- A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma
- (2008) D. V. Gold et al. CANCER RESEARCH
- A rapid point of care immunoswab assay for SARS-CoV detection
- (2008) Sriram Kammila et al. JOURNAL OF VIROLOGICAL METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now